SAN DIEGO, May 27, 2021 /PRNewswire/ — Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against ChemoCentryx, Inc. (NASDAQ: CCXI) (“ChemoCentryx” or the “Company”) for violations of federal securities laws.
On or about June 10, 2020, ChemoCentryx sold 5.2 million shares of stock in an underwritten public offering at $58.00 a share, raising over $300 million in new capital.
On May 27, 2021, ChemoCentryx stock closed at $10.41.
The investigation focuses on whether the Company issued false and misleading statements and failed to disclose information pertinent to investors. If you purchased ChemoCentryx shares in the June 2020 public offering, and are interested in learning more about the investigation, please contact Jim Baker ([email protected]) at 619-814-4471. If emailing, please include a phone number.
Additionally, you can [Click here to join this action]. There is no cost or obligation to you.
About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.
Johnson Fistel, LLP
Jim Baker, 619-814-4471
SOURCE Johnson Fistel, LLP